These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31935015)

  • 1. Early Returns From the Era of Precision Medicine.
    Cutler DM
    JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
    [No Abstract]   [Full Text] [Related]  

  • 2. Tackling Cost: A Prescription for Spending Wisely.
    Tempero M
    J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
    [No Abstract]   [Full Text] [Related]  

  • 3. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 4. NICE, the NHS, and Cancer Drugs.
    Dillon A; Landells LJ
    JAMA; 2018 Feb; 319(8):767-768. PubMed ID: 29387883
    [No Abstract]   [Full Text] [Related]  

  • 5. The economic crisis and cancer chemotherapy: the role of the oncologist.
    Rescigno P; Imbevaro S; Jirillo A
    Tumori; 2012; 98(4):532-3. PubMed ID: 23052172
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost of Cancer Drugs: Something Has To Give.
    Bender E
    Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limits to Personalized Cancer Medicine.
    Tannock IF; Hickman JA
    N Engl J Med; 2016 Sep; 375(13):1289-94. PubMed ID: 27682039
    [No Abstract]   [Full Text] [Related]  

  • 8. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer drug prices and the free-market forces.
    Kantarjian H; Zwelling L
    Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
    [No Abstract]   [Full Text] [Related]  

  • 11. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

  • 12. Value in Oncology: It Is in the Eyes of the Beholder.
    Nabhan C; Phillips EG; Feinberg BA
    J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
    [No Abstract]   [Full Text] [Related]  

  • 13. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
    Nadauld LD; Ford JM; Pritchard D; Brown T
    Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
    Huntington SF; Davidoff AJ; Gross CP
    J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
    [No Abstract]   [Full Text] [Related]  

  • 16. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

  • 17. Keynote comment: reimbursement for molecularly targeted anticancer agents.
    Tirelli U; de Castro G; Awada A
    Lancet Oncol; 2006 Jan; 7(1):2-3. PubMed ID: 16389172
    [No Abstract]   [Full Text] [Related]  

  • 18. ASCO Rx for high drug costs: doctors and patients need to talk.
    Nicholas J
    J Natl Cancer Inst; 2009 Nov; 101(21):1441-4. PubMed ID: 19828870
    [No Abstract]   [Full Text] [Related]  

  • 19. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
    Garrison LP
    Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
    [No Abstract]   [Full Text] [Related]  

  • 20. Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy.
    Eaglstein WH
    JAMA Dermatol; 2016 Feb; 152(2):139-40. PubMed ID: 26606648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.